Hollencrest Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Hollencrest Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-120,000	Closed	-$143K	–	1153
2022 Q3	$143K	Hold	120,000	–	–	0.02%	266
2022 Q2	$216K	Hold	120,000	–	–	0.03%	264
2022 Q1	$242K	Hold	120,000	–	–	0.02%	294
2021 Q4	$325K	Buy	120,000 +80,000	+200%	+$296K	0.03%	265
2021 Q3	$178K	Hold	40,000	–	–	0.02%	336
2021 Q2	$232K	Buy	40,000 +25,000	+167%	+$146K	0.02%	314
2021 Q1	$105K	Buy	+15,000	New	+$101K	0.01%	351

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Hollencrest Capital Management's CLVS Position: Q4 2022 in Review

Hollencrest Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 120,000 shares — an estimated $143K sold.

Hollencrest Capital Management first reported a position in CLVS in Q1 2021 and held it in 7 quarters. The position peaked at $325K in Q4 2021. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Hollencrest Capital Management reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Hollencrest Capital Management sold 120,000 Clovis Oncology, Inc. shares in Q4 2022, an estimated $143K.
Hollencrest Capital Management first reported a position in Clovis Oncology, Inc. in Q1 2021 and held it in 7 quarters.
Hollencrest Capital Management's Clovis Oncology, Inc. position peaked at $325K in Q4 2021.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Hollencrest Capital Management's 13F filing for Q4 2022, filed 7 Feb 2023.